R.H. Investment Group LLC Invests $3.62 Million in Johnson & Johnson (NYSE:JNJ)

R.H. Investment Group LLC acquired a new position in Johnson & Johnson (NYSE:JNJ - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 25,051 shares of the company's stock, valued at approximately $3,623,000. Johnson & Johnson accounts for 3.4% of R.H. Investment Group LLC's portfolio, making the stock its 18th largest holding.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Pines Wealth Management LLC purchased a new stake in Johnson & Johnson in the fourth quarter valued at approximately $477,000. SeaCrest Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 1.5% in the 4th quarter. SeaCrest Wealth Management LLC now owns 25,087 shares of the company's stock valued at $3,628,000 after buying an additional 374 shares during the period. Accurate Wealth Management LLC lifted its stake in Johnson & Johnson by 8.4% during the 4th quarter. Accurate Wealth Management LLC now owns 23,214 shares of the company's stock worth $3,298,000 after acquiring an additional 1,806 shares in the last quarter. Wynn Capital LLC boosted its holdings in Johnson & Johnson by 1.4% during the 4th quarter. Wynn Capital LLC now owns 12,647 shares of the company's stock valued at $1,829,000 after acquiring an additional 178 shares during the period. Finally, Fiduciary Financial Group LLC grew its position in Johnson & Johnson by 5.8% in the 4th quarter. Fiduciary Financial Group LLC now owns 4,370 shares of the company's stock valued at $621,000 after acquiring an additional 240 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Insider Buying and Selling

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares of the company's stock, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ traded down $0.74 during trading hours on Friday, reaching $147.03. The stock had a trading volume of 10,678,393 shares, compared to its average volume of 6,880,262. The firm has a market cap of $353.99 billion, a price-to-earnings ratio of 21.28, a PEG ratio of 2.30 and a beta of 0.51. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85. The firm has a 50-day moving average of $148.51 and a 200-day moving average of $155.96. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. During the same period last year, the firm posted $2.66 earnings per share. The company's revenue for the quarter was up 5.2% compared to the same quarter last year. Equities research analysts predict that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.37%. Johnson & Johnson's dividend payout ratio (DPR) is 71.78%.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on JNJ. Guggenheim raised their price objective on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a "neutral" rating in a research note on Wednesday, November 6th. Citigroup dropped their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating for the company in a research note on Wednesday, December 11th. Royal Bank of Canada increased their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the company an "outperform" rating in a research note on Wednesday, October 16th. Morgan Stanley boosted their target price on Johnson & Johnson from $169.00 to $175.00 and gave the stock an "equal weight" rating in a research note on Wednesday, October 16th. Finally, Wells Fargo & Company increased their price target on Johnson & Johnson from $163.00 to $166.00 and gave the company an "equal weight" rating in a research report on Wednesday, October 16th. Seven equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus target price of $174.29.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.